Ezekiel Emanuel of the Perelman School of Medicine and the Wharton School shares his thoughts about pharmaceutical companies providing funding for patient groups while stifling the groups’ voice in the debate over increasing drug prices.
http://www.usatoday.com/story/news/nation/2016/01/21/patient-groups-drug-makers-high-drug-prices/79001722/ USA Today